An official FDA list of medications currently in short supply. It matters for GLP-1s because, while a drug is listed, pharmacies are allowed to compound copies of it — the legal basis for the compounded-semaglutide boom. When the FDA declared the semaglutide and tirzepatide shortages resolved in 2024–2025, that exception closed, and mass-market compounding of copies became an enforcement target.
Related terms: Compounded medication · FDA approval